791P Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway
Year: 2024
Type: article
Source: Annals of Oncology
Authors: G. Shapiro, J.E. Ang, E. Castanon Alvarez, A.I. Spira, P. Cassier, P. Lorusso, S. Gaillard, H.A. Chen, S. Kummar, M.G. Krebs, R. Plummer, E. Carcereny, E. Meshoulam Nikolaeva, J. Munck, D. Chan, M. Dijkstra, H.N. Keer, E.K. Lee
Institutions: Dana-Farber Cancer Institute, Cambridge University Hospitals NHS Foundation Trust, Clinica Universidad de Navarra, Virginia Cancer Specialists, Centre Léon Bérard, Yale Cancer Center, Yale University, Smilow Cancer Hospital, Johns Hopkins University, UC Davis Comprehensive Cancer Center, Oregon Health & Science University, OHSU Knight Cancer Institute, The Christie NHS Foundation Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, Hospital Universitari Germans Trias i Pujol, Instituto Oncológico Dr. Rosell, Taiho Oncology (United States)
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4402558690